Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology
China Biotechnology  2017, Vol. 37 Issue (12): 90-95    DOI: 10.13523/j.cb.20171213
Orginal Article     
Advance in Immunotherapy Research of Hepatocellular Carcinoma Targeting Glypican-3
Lin YU1,2,Jian-hua WANG2*,Liang-peng GE1,3,4*
1 Chongqing Academy of Animal Sciences,Chongqing 402460, China
2 Bioengineering College of Chongqing University, Chongqing 400044, China
3 Key Laboratory of Pig Industry Sciences, Ministry of Agriculture,Chongqing 402460, China
4 Chongqing Key Laboratory of Pig Industry Sciences,Chongqing 402460, China
Download: HTML   PDF(530KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Researchs shows that Glypican-3 expresses in hepatocellular carcinoma (HCC) patients with high specificity and is closely related to development of hepatocarcinoma. Including therapeutic antibody,Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) , immunotoxin and vaccine are the focus of targeting Glypican-3 for immunotherapy in HCC at present. The structure and function of Glypican-3 is reviewed, as well as the progress of immunotherapy based on Glypican-3 in HCC is briefly described.

Key words： Glypican-3      HCC      Immunotherapy      Antibody      CAR-T     
Received: 22 June 2017      Published: 16 December 2017
ZTFLH:  Q819  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Lin YU
Jian-hua WANG
Liang-peng GE
Cite this article:

Lin YU,Jian-hua WANG,Liang-peng GE. Advance in Immunotherapy Research of Hepatocellular Carcinoma Targeting Glypican-3. China Biotechnology, 2017, 37(12): 90-95.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20171213     OR     https://manu60.magtech.com.cn/biotech/Y2017/V37/I12/90

Fig.1 Schematic structure of Glypican-3
Fig.2 Positive effect of Glypican-3 on HCC
名称抗体类型研究阶段文献
GC33IgG,人源化临床二期(已完成)[33-36]
YP7IgG,人源化临床前[37]
HN3VH-hFc,全人源临床前[38]
HS20scFv,全人源临床前[40, 53]
ERY974GPC3/CD3-bispecific antibody,人源化临床一期https://clinicaltrials.gov/NCT02748837
Table 1 Study of therapeutic antibodies targeting Glypican-3 in HCC
临床标识号开始时间研究阶段联合治疗研究机构
NCT023952502015年3月临床一期(已终止)无上海仁济医院
NCT027239422015年6月临床一期无广州复大肿瘤医院
NCT027153622016年3月临床一期无上海吉凯基因化学公司
NCT031307122017年4月临床一期无上海吉凯基因化学公司
NCT031462342017年3月临床一期无上海仁济医院
上海科济生物医药公司
NCT030843802017年6月临床一期肝肿瘤经动脉化疗栓塞
(氟达拉滨、环磷酰胺)		重庆新桥医院
NCT029051882018年1月临床一期淋巴细胞删除性化疗
(氟达拉滨、环磷酰胺)		美国贝勒医学院
Table 2 Clinical study of CAR-T therapy targeting Glypican-3 in HCC
[1]   Torre L A, Bray F, Siegel R L, et al.Global cancer statistics, 2012 . CA: A Cancer Journal for Clinicians, 2015, 65(2): 87-108.
doi: 10.3322/caac.21262
[2]   Torre L A, Siegel R L, Ward E M, et al.Global cancer incidence and mortality rates and trends—an update. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2016, 25(1): 16-27.
[3]   Galle P R.Sorafenib in advanced hepatocellular carcinoma - We have won a battle not the war. J Hepatol, 2008, 49(5): 871-873.
doi: 10.1016/j.jhep.2008.09.001 pmid: 18817997
[4]   Ohri N, Kaubisch A, Ggrg M, et al.Targeted therapy for hepatocellular carcinoma. Semin Radiat Oncol, 2016, 26(4): 338-343.
doi: 10.1016/j.semradonc.2016.06.004 pmid: 27619254
[5]   Filmus J, Shi W, Wong Z M, et al.Identification of a new membrane-bound heparan sulphate proteoglycan. The Biochemical Journal, 1995, 311( Pt 2):561-565.
doi: 10.1042/bj3110561 pmid: 7487896
[6]   Filmus J, Capurro M, Rast J.Glypicans. Genome Biology, 2008, 9(5): 224.
doi: 10.1186/gb-2008-9-5-224
[7]   Hippo Y, Watanabe K, Watanabe A, et al.Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Research, 2004, 64(7): 2418-2423.
doi: 10.1158/0008-5472.CAN-03-2191
[8]   Ho M, Kim H.Glypican-3: a new target for cancer immunotherapy. European Journal of Cancer, 2011, 47(3): 333-338.
doi: 10.1016/j.ejca.2010.10.024 pmid: 3031711
[9]   Filmus J, Church J G, Buick R N.Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Molecular and Cellular Biology, 1988, 8(10): 4243-4249.
doi: 10.1128/MCB.8.10.4243 pmid: 365496
[10]   Song H H, Filmus J.The role of glypicans in mammalian development. Biochimica et Biophysica Acta, 2002, 1573(3): 241-246.
doi: 10.1016/S0304-4165(02)00390-2 pmid: 12417406
[11]   Iglesias B V, Centeno G, Pascuccelli H, et al.Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histology and Histopathology, 2008, 23(11): 1333-1340.
doi: 10.1016/j.heares.2008.09.003 pmid: 18785116
[12]   Pilia G, Hughesbenzie R M, Mackenzie A, et al.Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nature Genetics, 1996, 12(3): 241-247.
doi: 10.1038/ng0396-241
[13]   Song H H, Shi W, Filmus J.OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. The Journal of Biological Chemistry, 1997, 272(12): 7574-7577.
doi: 10.1074/jbc.272.12.7574 pmid: 9065409
[14]   Veugelers M, Cat B D, Muyldermans S Y, et al.Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-function mutations in the GPC3 gene. Human Molecular Genetics, 2000, 9(9): 1321-1328.
doi: 10.1007/BF02864550 pmid: 10814714
[15]   Capurro M I, Xu P, Shi W, et al.Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Developmental Cell, 2008, 14(5): 700-711.
doi: 10.1016/j.devcel.2008.03.006 pmid: 18477453
[16]   Filmus J.Glypicans in growth control and cancer. Glycobiology, 2001, 11(3): 19-23.
doi: 10.1093/glycob/11.3.19R pmid: 11320054
[17]   Xiang Y Y, Ladeda V, Filmus J.Glypican-3 expression is silenced in human breast cancer. Oncogene, 2001, 20(50): 7408-7412.
doi: 10.1038/sj.onc.1204925 pmid: 11704870
[18]   Wichert A, Stege A, Midorikawa Y, et al.Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Oncogene, 2004, 23(4): 945-955.
doi: 10.1111/j.1440-1827.2006.01962.x pmid: 14661052
[19]   Lin H, Huber R, Schlessinger D, et al.Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res, 1999, 59(4): 807-810.
doi: 10.1136/injuryprev-2012-040686 pmid: 10029067
[20]   Murthy S S, Shen T, De Rienzo A, et al.Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene, 2000, 19(3): 410-416.
doi: 10.1038/sj.onc.1203322
[21]   Sung Y K, Hwang S Y, Park M K, et al.Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Science, 2003, 94(3): 259-262.
doi: 10.1016/j.healun.2007.07.015 pmid: 12824919
[22]   Baumhoer D, Tornillo L, Stadlmann S, et al.Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4 387 tissue samples. American Journal of Clinical Pathology, 2008, 129(6): 899-906.
doi: 10.1309/HCQWPWD50XHD2DW6
[23]   Hsu H C, Cheng W, Lai P L.Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res, 1997, 57(22): 5179-5184.
pmid: 9371521
[24]   Zhu Z W, Friess H, Wang L, et al.Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 2001, 48(4): 558-564.
doi: 10.1136/gut.48.4.558 pmid: 11247902
[25]   Yamauchi N, Watanabe A, Hishinuma M, et al.The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Modern Pathology, 2005, 18(12): 1591-1598.
doi: 10.1038/modpathol.3800436 pmid: 15920546
[26]   Haruyama Y, Yorita K, Yamaguchi T, et al.High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. Int J Cancer, 2015, 137(7): 1643-1651.
doi: 10.1002/ijc.29518 pmid: 25784484
[27]   Capurro M I, Xiang Y-Y, Lobe C, et al.Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Research, 2005, 6245-6254.
doi: 10.1158/0008-5472.CAN-04-4244 pmid: 16024626
[28]   Capurro M, Martin T, Shi W, et al.Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. Journal of Cell Science, 2014, 127(Pt 7): 1565-1575.
doi: 10.1242/jcs.140871 pmid: 24496449
[29]   Wands J R, Kim M.WNT/beta-catenin signaling and hepatocellular carcinoma. Hepatology, 2014, 60(2): 452-454.
doi: 10.1002/hep.v60.2
[30]   Hann S R.Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. Seminars in Cancer Biology, 2006, 16(4): 288-302.
doi: 10.1016/j.semcancer.2006.08.004 pmid: 16938463
[31]   Li L, Jin R, Zhang X, et al.Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma. Hepatology, 2012, 56(4): 1380-1390.
doi: 10.1002/hep.25891 pmid: 22706665
[32]   Wu Y, Liu H, Weng H, et al.Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. International Journal of Oncology, 2015, 46(3): 1275-1285.
doi: 10.3892/ijo.2015.2827 pmid: 255726153
[33]   Ishiguro T, Sugimoto M, Kinoshita Y, et al.Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res, 2008, 68(23): 9832-9838.
doi: 10.1158/0008-5472.CAN-08-1973 pmid: 19047163
[34]   Nakano K, Orita T, Nezu J, et al.Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun, 2009, 378(2): 279-284.
doi: 10.1016/j.bbrc.2008.11.033 pmid: 19022220
[35]   Nakano K, Ishiguro T, Konishi H, et al.Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anti Cancer Drugs, 2010, 21(10): 907-916.
doi: 10.1097/CAD.0b013e32833f5d68 pmid: 20847643
[36]   Abou-Alfa G K, Pyig O, Daniele B, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol, 2016, 65(2): 289-295.
doi: 10.1016/j.jhep.2016.04.004 pmid: 27085251
[37]   Phung Y, Gao W, Man Y G, et al.High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. mAbs, 2012, 4(5): 592-599.
doi: 10.4161/mabs.20933 pmid: 22820551
[38]   Feng M, Gao W, Wang R, et al.Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 2013, 110(12): 1083-1091.
doi: 10.1073/pnas.1214255110
[39]   Hanaoka H, Nagaya T, Sato K, et al.Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy. Molecular Pharmaceutics, 2015, 12(6): 2151-2157.
doi: 10.1021/acs.molpharmaceut.5b00132 pmid: 25955255
[40]   Wong C M, Gao W, Kim H, et al.Human monoclonal antibody targeting the heparan sulfate chains of glypican-3 inhibits HGF-mediated migration and motility of hepatocellular carcinoma cells. PloS One, 2015, 10(9): e0137664.
doi: 10.1371/journal.pone.0137664 pmid: 4557904
[41]   Couzin-Frankel J.Breakthrough of the year 2013. cancer immunotherapy. Science, 2013, 342(6165): 1432-1433.
doi: 10.1126/science.342.6165.1432
[42]   Gao H, Li K, Tu H, et al.Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clinical Cancer Research, 2014, 20(24): 6418-6428.
doi: 10.1158/1078-0432.CCR-14-1170 pmid: 25320357
[43]   Jiang Z, Jiang X, Chen S, et al. Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma. Frontiers in Immunology, 2016, 7:1-10.
doi: 10.3389/fimmu.2016.00690 pmid: 28123387
[44]   Roybal K T, Rupp L J, Morsut L, et al.Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell, 2016, 164(4): 770-779.
doi: 10.1016/j.cell.2016.01.011 pmid: 26830879
[45]   Chen C, Li K, Jiang H, et al.Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunology, Immunotherapy : CII, 2017, 66(4): 475-489.
doi: 10.1007/s00262-016-1949-8 pmid: 28035433
[46]   Gao W, Tang Z, Zhang Y F, et al. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nature Communications, 2015, 6:1-26.
doi: 10.1038/ncomms7536 pmid: 4357278
[47]   Wang C, Gao W, Feng M, et al.Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy. Oncotarget, 2017, 8(20): 32450-32460.
doi: 10.18632/oncotarget.10592 pmid: 27419635
[48]   Komori H, Nakatsura T, Senju S, et al.Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clinical Cancer Research, 2006, 12(9): 2689-2697.
doi: 10.1158/1078-0432.CCR-05-2267 pmid: 16675560
[49]   Motomura Y, Ikuta Y, Kuronuma T, et al.HLA-A2 and-A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: Preclinical study using mice. Int J Oncol, 2008, 32(5): 985-990.
doi: 10.1046/j.1460-9568.2003.02964.x pmid: 18425324
[50]   Iwama T, Horie K, Yoshikawa T, et al.Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. Int J Oncol, 2013, 42(3): 831-838.
doi: 10.3892/ijo.2013.1793 pmid: 23354275
[51]   Sawada Y, Yoshikawa T, Nobuoka D, et al.Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clinical Cancer Research, 2012, 18(13): 3686-3696.
doi: 10.1158/1078-0432.CCR-11-3044 pmid: 22577059
[52]   Iwama T, Uchida T, Sawada Y, et al.Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice. Biochemical and Biophysical Research Communications, 2016, 469(1): 138-143.
doi: 10.1016/j.bbrc.2015.11.084 pmid: 26616051
[53]   Gao W, Kim H, Feng M, et al.Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology, 2014, 60(2): 576-587.
doi: 10.1002/hep.26996 pmid: 244929433
[54]   Neves H, Kwok H F.Recent advances in the field of anti-cancer immunotherapy. BBA Clinical, 2015, 3:280-288.
doi: 10.1016/j.bbacli.2015.04.001 pmid: 935
[55]   Feng M, Kim H, Phung Y, et al.Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. International Journal of Cancer, 2011, 128(9): 2246-2247.
doi: 10.1002/ijc.25549 pmid: 20617511
[56]   Wang H L, Anatelli F, Zhai Q J, et al.Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Archives of Pathology & Laboratory Medicine, 2008, 132(11): 1723-1728.
doi: 10.1043/1543-2165-132.11.1723 pmid: 18976006
[57]   Qin Z, Wang J, Wang Y, et al. Identification of a glypican-3-binding peptide for in vivo non-invasive human hepatocellular carcinoma detection. Macromolecular Bioscience, 2016,1-10.
doi: 10.1002/mabi.201600335 pmid: 27862961
[58]   Sawada Y, Yisgikawa T, Ofuji K, et al.Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology, 2016, 5(5): e1129483.
doi: 10.1080/2162402X.2015.1129483 pmid: 27467945
[1] CHEN Xiu-yue,ZHOU Wen-feng,HE Qing,SU Bing,ZOU Ya-wen. Preparation, Purification and Identification of Bacteriophage Qβ Virus-like Particles[J]. China Biotechnology, 2021, 41(7): 42-49.
[2] CHEN Wen-jie,MIAO Xian-feng. Domestic Research and Development Status of Antibody-drug Conjugates and Strategic Layout of Key Enterprises[J]. China Biotechnology, 2021, 41(6): 105-110.
[3] XU Ye-chun,LIU Hong,LI Jian-feng,SHEN Jing-shan,JIANG Hua-liang. Recent Progress in Drug Development against COVID-19[J]. China Biotechnology, 2021, 41(6): 111-118.
[4] YUAN Bo,WANG Jie-wen,KANG Guang-bo,HUANG He. Research Progress and Application of Bispecific Nanobody[J]. China Biotechnology, 2021, 41(2/3): 78-88.
[5] MAO Kai-yun,LI Rong,LI Dan-dan,ZHAO Ruo-chun,FAN Yue-lei,JIANG Hong-bo. Analysis of the Current Status of Global Bispecific Antibody Development[J]. China Biotechnology, 2021, 41(11): 110-118.
[6] ZHAO Yan-shu,ZHANG Jin-hua,SONG Hao. Advances in Production of Monoclonal Antibody and Antibody Fragments in Engineered Prokaryotes and Yeast[J]. China Biotechnology, 2020, 40(8): 74-83.
[7] YANG Xiao-ying,LI Meng,ZHAO Wei,TANG Min,ZHANG Zhi-qian. Preparation and Preliminary Characterization of Anti-α2δ1/CD3 Bispecific Antibody[J]. China Biotechnology, 2020, 40(7): 9-14.
[8] WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi,SUN Yan-rong. Development and Prospect of Antibody Drugs for SARS-CoV-2[J]. China Biotechnology, 2020, 40(5): 1-6.
[9] WANG Meng,SONG Hui-ru,CHENG Yu-jie,WANG Yi,YANG Bo,HU Zheng. Accurate Detection of Streptococcus pneumoniae by Using Ribosomal Protein L7 / L12 as Molecular Marker[J]. China Biotechnology, 2020, 40(4): 34-41.
[10] YANG Li,SHI Xiao-yu,LI Wen-lei,LI Jian,XU Han-mei. Optimization of Electroporation Conditions in Construction of Phage Display Antibody Library[J]. China Biotechnology, 2020, 40(4): 42-48.
[11] LI Tong-tong,SONG Cai-ling,YANG Kai-yue,WANG Wen-jing,CHEN Hui-yu,LIU Ming. Preparation and Neutralization Activity of Anti-Canine Parvovirus VP2 Protein Single-chain Antibody[J]. China Biotechnology, 2020, 40(4): 10-16.
[12] CHEN Qiu-li,YANG Li-chao,LI Hui,WEN Sha,LI Gang,HE Min. Prokaryotic Expression,Purification and Preparation of Polyclonal Antibody of Human Nek2 Protein[J]. China Biotechnology, 2020, 40(3): 31-37.
[13] PAN Tong-tong,CHEN Yong-ping. Research Progress of Key Techniques for Severe/Critical Type of Novel Coronavirus Pneumonia[J]. China Biotechnology, 2020, 40(1-2): 78-83.
[14] LI Dong-qiao,LV Lu-cheng,YANG Yan-ping. The Research Status and Development Trend of Global Human Coronavirus Antibody Field[J]. China Biotechnology, 2020, 40(1-2): 65-70.
[15] KONG Jian-tao,ZHUANG Ying-ping,GUO Mei-jin. Enhancement of Anti-CD20 Monoclonal Antibody Expression by CHO based on DOE and Amino Acid Supplemental Strategy[J]. China Biotechnology, 2020, 40(12): 41-48.
主管：中国科学院 　主办：中国科学院文献情报中心 　中国生物技术发展中心 　中国生物工程学会